ClinicalTrials.gov
ClinicalTrials.gov Menu

Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01573637
Recruitment Status : Completed
First Posted : April 9, 2012
Last Update Posted : August 24, 2015
Sponsor:
Collaborators:
Hospital Sant Joan de Deu
Parc Sanitari Sant Joan de Déu
Stanley Medical Research Institute
Information provided by (Responsible Party):
Fundació Sant Joan de Déu

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2014
  Actual Study Completion Date : July 2014
Publications of Results:
Other Publications:
Riecher-Rössler A, Häfner H, Maurer K, Stummbaum M, Schmitd R. Schizophrenia symptomatology varies with serum estradiol levels during menstrual cycle. Schizophrenia Research 1992; 6: 114-115.
Häfner H. Gender differences in first-episode of schizophrenia. In Frank ed, gender and its effects in Psychopathology. American Psychiatric Press, Washington 2000

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):